lenalidomide has been researched along with Hypopituitarism in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bing, X; Peifang, L | 1 |
| Hamnvik, OP; Larsen, PR; Marqusee, E | 1 |
1 review(s) available for lenalidomide and Hypopituitarism
| Article | Year |
|---|---|
Thyroid dysfunction from antineoplastic agents.
Topics: Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Anticarcinogenic Agents; Antineoplastic Agents; Bexarotene; Diphtheria Toxin; Humans; Hyperthyroidism; Hypopituitarism; Hypothyroidism; Interferon-alpha; Interleukin-2; Iodine Radioisotopes; Ipilimumab; Lenalidomide; Molecular Targeted Therapy; Neoplasms; Protein-Tyrosine Kinases; Quality of Life; Radioimmunotherapy; Recombinant Fusion Proteins; Recombinant Proteins; Tetrahydronaphthalenes; Thalidomide; Thyroid Function Tests; Thyroid Gland; Thyroid Hormones; Thyroiditis, Autoimmune | 2011 |
1 other study(ies) available for lenalidomide and Hypopituitarism
| Article | Year |
|---|---|
Treatment-triggered onset and diagnosis of Sheehan syndrome in a multiple myeloma patient.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Female; Humans; Hypopituitarism; Immunologic Factors; Lenalidomide; Magnetic Resonance Imaging; Multiple Myeloma; Pituitary Gland; Positron Emission Tomography Computed Tomography; Treatment Outcome | 2019 |